150 related articles for article (PubMed ID: 1768046)
41. Carcinogen susceptibility is regulated by genome architecture and predicts cancer mutagenesis.
García-Nieto PE; Schwartz EK; King DA; Paulsen J; Collas P; Herrera RE; Morrison AJ
EMBO J; 2017 Oct; 36(19):2829-2843. PubMed ID: 28814448
[TBL] [Abstract][Full Text] [Related]
42. Sustaining cancer through addictive ectopic gene activation.
Wang J; Rousseaux S; Khochbin S
Curr Opin Oncol; 2014 Jan; 26(1):73-7. PubMed ID: 24275853
[TBL] [Abstract][Full Text] [Related]
43. Potential therapeutic targets in multistep oncogenesis.
Burns PA; Balmain A
Semin Cancer Biol; 1992 Dec; 3(6):335-41. PubMed ID: 1286154
[TBL] [Abstract][Full Text] [Related]
44. [Mutator hypothesis of carcinogenesis and supermutagens in anticancer therapy].
Krutiakov VM
Vestn Ross Akad Med Nauk; 2009; (9):39-43. PubMed ID: 19827641
[TBL] [Abstract][Full Text] [Related]
45. [Antineoplastic drugs: resistance and metabolism].
Lavigne JG
Union Med Can; 1976 Feb; 105(2):186-8. PubMed ID: 996993
[No Abstract] [Full Text] [Related]
46. Molecular and clinical advances in anticancer drug resistance.
Cancer Treat Res; 1991; 57():1-308. PubMed ID: 1686711
[No Abstract] [Full Text] [Related]
47. The potential of protein kinase C as a target for anticancer treatment.
Basu A
Pharmacol Ther; 1993 Sep; 59(3):257-80. PubMed ID: 8309991
[TBL] [Abstract][Full Text] [Related]
48. Drug resistance as a dynamic process in a model for multistep gene amplification under various levels of selection stringency.
Harnevo LE; Agur Z
Cancer Chemother Pharmacol; 1992; 30(6):469-76. PubMed ID: 1394803
[TBL] [Abstract][Full Text] [Related]
49. The 'cancell' theory of carcinogenesis: re-evolution of an ancient, holistic neoplastic unicellular concept of cancer.
Grossgebauer K
Med Hypotheses; 1995 Dec; 45(6):545-55. PubMed ID: 8771049
[TBL] [Abstract][Full Text] [Related]
50. [Mechanisms of tumoral resistance to antineoplastic agents].
Albiero AL; Pozzi DH
Rev Assoc Med Bras (1992); 1994; 40(2):125-8. PubMed ID: 7820150
[No Abstract] [Full Text] [Related]
51. Tumour heterogeneity and the evolutionary trade-offs of cancer.
Hausser J; Alon U
Nat Rev Cancer; 2020 Apr; 20(4):247-257. PubMed ID: 32094544
[TBL] [Abstract][Full Text] [Related]
52. A unifying concept of carcinogenesis and its therapeutic implications.
Smith AE; Kenyon DH
Oncology; 1973; 27(5):459-79. PubMed ID: 4578174
[No Abstract] [Full Text] [Related]
53. Development and the environment: clues to carcinogenesis.
Potter JD
Cancer Epidemiol Biomarkers Prev; 2011 Apr; 20(4):574-7. PubMed ID: 21454419
[No Abstract] [Full Text] [Related]
54. Some aspects of cancer medicine.
Malpas JS
J R Coll Physicians Lond; 1994; 28(2):136-142. PubMed ID: 8006866
[TBL] [Abstract][Full Text] [Related]
55. Mycoplasmas, transposons and neoplasia.
van der Riet FD; Renan MJ
Res Virol; 1992; 143(6):429-30. PubMed ID: 1338401
[No Abstract] [Full Text] [Related]
56. Drug metabolism in carcinogenesis and cancer chemotherapy.
Graham MA; Riley RJ; Kerr DJ
Pharmacol Ther; 1991; 51(2):275-89. PubMed ID: 1784632
[TBL] [Abstract][Full Text] [Related]
57. Future potential of adjuvant and neoadjuvant therapy.
Yarbro JW
Semin Oncol; 1991 Dec; 18(6):613-9. PubMed ID: 1775978
[No Abstract] [Full Text] [Related]
58. Understanding of the molecular basis of drug resistance in cancer reveals new targets for chemotherapy.
Dickson RB; Gottesman MM
Trends Pharmacol Sci; 1990 Aug; 11(8):305-7. PubMed ID: 2203190
[No Abstract] [Full Text] [Related]
59. The recurrent architecture of tumour initiation, progression and drug sensitivity.
Califano A; Alvarez MJ
Nat Rev Cancer; 2017 Feb; 17(2):116-130. PubMed ID: 27977008
[TBL] [Abstract][Full Text] [Related]
60. [CARCINOGENESIS, CURRENT HYPOTHESES, ANTICANCER CHEMOTHERAPY].
MARAL R
Rev Lyon Med; 1965 Jan; 14():47-65. PubMed ID: 14298627
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
